X4 Pharmaceuticals Inc (XFOR) Stock Price, Quote & News

Company Profile

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical tri...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 529 8300

Website: www.x4pharma.com

Address:

61 North Beacon Street, 4th Floor, Boston, United States

WickedShadow Dec. 4 at 4:45 PM

Massive news on ticker DEVS🚀 DevvStream And Southern Energy Secure Louisiana Community Development Authority Approval For $402M Biomass-To-Fuel Facility Project DEVS is starting to squeeze on this news, make sure to keep eyes on it. With 2M float this can make a massive move soon!! $PAVS $SMX $XFOR $ASTS ,,./

0 · Reply

Pinecone_Tradingz_ Dec. 4 at 4:41 PM

Banked up $8.4K profits on that run! Thank you! Made my whole month! Make sure you FOLLOW @ICEMAN_ALERTS below, Great trader!! He's been on fire recently, Keeping my port green 🙏 🔥 Breakout on $TIVC $TAOP $XFOR $ILLR also

0 · Reply

HTNY Dec. 1 at 9:57 AM

The 'I hate biotech' list. Note these have 10x or 0.1x potential and are massively speculative. I personally hate biotech as valuing companies that are impossible to properly value is a silly game. Tread carefully and do not overload any single position. $XLO $ITRM $MLTX $XFOR $MCRB

5 · Reply

Iightning Nov. 26 at 5:13 AM

1ightning® Options Trade Alert (Actionable) | Buy $XFOR Jan 16 $3 Call | Enter: $0.05 Exit: $0.06 | Profit: 25.88% ROI | https://1ightning.com

0 · Reply

Harold_the_Hedge Nov. 25 at 8:13 PM

$XFOR lets see sub 1

1 · Reply

Iightning Nov. 25 at 3:21 PM

1ightning® Options Trade Alert (Actionable) | Buy $XFOR Jan 16 $3 Call | Enter: $0.05 Exit: $0.06 | Profit: 25.88% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 4:16 AM

1ightning® Options Trade Alert (Actionable) | Buy $XFOR Jan 16 $3 Call | Enter: $0.05 Exit: $0.06 | Profit: 25.88% ROI | https://1ightning.com

0 · Reply

Pope25 Nov. 24 at 7:05 PM

$XFOR legit ded for the next 18 months isnt it?

1 · Reply

Iightning Nov. 22 at 1:27 AM

1ightning® Options Trade Alert (Actionable) | Buy $XFOR Jan 16 $3 Call | Enter: $0.05 Exit: $0.09 | Profit: 79.08% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 21 at 4:49 AM

1ightning® Options Trade Alert (Actionable) | Buy $XFOR Jan 16 $3 Call | Enter: $0.05 Exit: $0.09 | Profit: 79.08% ROI | https://1ightning.com

0 · Reply

X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia

Nov 5, 2025, 4:01 PM EST - 4 weeks ago

X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference

Nov 5, 2025, 7:00 AM EST - 4 weeks ago

X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 27, 2025, 7:05 PM EDT - 5 weeks ago

X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

Oct 24, 2025, 12:37 AM EDT - 5 weeks ago

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

Oct 23, 2025, 4:01 PM EDT - 6 weeks ago

X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

Sep 17, 2025, 7:00 AM EDT - 2 months ago

X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation

Aug 15, 2025, 4:05 PM EDT - 3 months ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 13, 2025, 7:00 AM EDT - 4 months ago

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

Aug 12, 2025, 7:00 AM EDT - 4 months ago

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

Jun 16, 2025, 8:00 AM EDT - 6 months ago

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

Jun 10, 2025, 8:00 AM EDT - 6 months ago

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

May 14, 2025, 4:12 PM EDT - 7 months ago

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

May 1, 2025, 12:44 PM EDT - 7 months ago

X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript

May 1, 2025, 6:01 AM EDT - 7 months ago

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Apr 28, 2025, 7:16 AM EDT - 7 months ago

Top 3 Health Care Stocks That May Rocket Higher In April

BMY UNH

Apr 24, 2025, 8:03 AM EDT - 8 months ago

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

Apr 24, 2025, 8:00 AM EDT - 8 months ago

X4 Pharmaceuticals Announces Reverse Stock Split

Apr 23, 2025, 4:05 PM EDT - 8 months ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 25, 2025, 3:02 PM EDT - 9 months ago

X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 6:01 AM EDT - 9 months ago

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 11, 2025, 8:00 AM EDT - 9 months ago

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

Feb 19, 2025, 7:35 AM EST - 10 months ago

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

Feb 6, 2025, 7:35 AM EST - 10 months ago

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

Jan 24, 2025, 7:36 AM EST - 11 months ago

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

Jan 13, 2025, 7:35 AM EST - 11 months ago

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

Nov 14, 2024, 8:00 AM EST - 1 year ago

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

Nov 13, 2024, 9:31 PM EST - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 6:07 AM EST - 1 year ago

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 6:01 AM EST - 1 year ago

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

Oct 24, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

Aug 28, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

Aug 10, 2024, 9:30 AM EDT - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Jul 2, 2024, 6:17 PM EDT - 1 year ago

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

Jun 27, 2024, 6:30 AM EDT - 1 year ago

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

Jun 24, 2024, 4:51 AM EDT - 1 year ago

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

MRK NTLA ARWR VRNA

May 29, 2024, 4:30 PM EDT - 1 year ago

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

May 13, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 9, 2024, 6:30 AM EDT - 1 year ago

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

May 7, 2024, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

Apr 30, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

Apr 29, 2024, 5:02 PM EDT - 1 year ago

X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside

Apr 29, 2024, 6:37 AM EDT - 1 year ago

US FDA approves X4 Pharmaceuticals' drug for immunodeficiency disease

Apr 29, 2024, 6:30 AM EDT - 1 year ago

X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome

Apr 1, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

Mar 21, 2024, 11:35 AM EDT - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q4 2023 Earnings Call Transcript

Mar 21, 2024, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Mar 12, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024

Dec 13, 2023, 11:43 PM EST - 2 years ago

X4: Dip Following Mixed Results In Chronic Neutropenia Indication Worth Buying

WickedShadow Dec. 4 at 4:45 PM

0 · Reply

Pinecone_Tradingz_ Dec. 4 at 4:41 PM

0 · Reply

HTNY Dec. 1 at 9:57 AM

5 · Reply

Iightning Nov. 26 at 5:13 AM

1ightning® Options Trade Alert (Actionable) | Buy $XFOR Jan 16 $3 Call | Enter: $0.05 Exit: $0.06 | Profit: 25.88% ROI | https://1ightning.com

0 · Reply

Harold_the_Hedge Nov. 25 at 8:13 PM

$XFOR lets see sub 1

1 · Reply

Iightning Nov. 25 at 3:21 PM

1ightning® Options Trade Alert (Actionable) | Buy $XFOR Jan 16 $3 Call | Enter: $0.05 Exit: $0.06 | Profit: 25.88% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 4:16 AM

1ightning® Options Trade Alert (Actionable) | Buy $XFOR Jan 16 $3 Call | Enter: $0.05 Exit: $0.06 | Profit: 25.88% ROI | https://1ightning.com

0 · Reply

Pope25 Nov. 24 at 7:05 PM

$XFOR legit ded for the next 18 months isnt it?

1 · Reply

Iightning Nov. 22 at 1:27 AM

1ightning® Options Trade Alert (Actionable) | Buy $XFOR Jan 16 $3 Call | Enter: $0.05 Exit: $0.09 | Profit: 79.08% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 21 at 4:49 AM

1ightning® Options Trade Alert (Actionable) | Buy $XFOR Jan 16 $3 Call | Enter: $0.05 Exit: $0.09 | Profit: 79.08% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 20 at 2:31 AM

1ightning® Options Trade Alert (Actionable) | Buy $XFOR Jan 16 $3 Call | Enter: $0.05 Exit: $0.09 | Profit: 79.08% ROI | https://1ightning.com

0 · Reply

DaBullRunner Nov. 19 at 3:07 PM

$XFOR told you about this one in the $1.70’s 🚨SDA🚨🤝 TESLA = $5+ 🎯✅ I’m even willing to put some of my COIN TSLA profits into SDA👇💰💰💰 $FRGT $ZYXI $EPWK $AZI what a day

0 · Reply

Iightning Nov. 19 at 10:24 AM

1ightning® Options Trade Alert (Actionable) | Buy $XFOR Jan 16 $3 Call | Enter: $0.05 Exit: $0.09 | Profit: 79.08% ROI | https://1ightning.com

0 · Reply

dl42 Nov. 15 at 3:34 PM

$XFOR i’m just going to buy on dips knowing i’m stuck here until 27’ if not longer🤷🏻‍♂️.

0 · Reply

Zkoko_Bio Nov. 15 at 9:42 AM

$XFOR The most useless investment I have made in my entire life. Simply the worst ! They should close it down, get delisted and go home.

0 · Reply

isaacwilliams33 Nov. 12 at 10:21 PM

$IMG $AQMS $TGL $SBEV $XFOR all had a decent day today

1 · Reply

Lol_at_ur_bags Nov. 12 at 5:48 PM

$CWD $JBIO $PTPI $XFOR Dude you’re hopping board to board glazing @invinc1ble. At least wipe the glizzy off before posting.

0 · Reply

Pangloss_0589 Nov. 12 at 12:25 PM

$XFOR i listened to the Guggenheim fireside Chat with the New X4 chairman Adam Craig. He seems bullish on the 4ward trial. However he also mentioned it was 1/3 of the way enrolled only, and that was the reason for the management shake up. This mean paula ragan had been lying about enrolment rates and timelines. Looks like too little effort was put on recruiting and too much on finding Whim patients. This strategic error and misleading communication cost her her job. Rightfully so, what a waste of precious time and money.

2 · Reply

GinoGino Nov. 11 at 12:27 AM

$XFOR Completely forgotten by investors, closes red followinga big PT raise! Someday, perhaps!

0 · Reply

JarvisFlow Nov. 10 at 12:09 PM

HC Wainwright & Co. has adjusted their stance on X4 Pharmaceuticals ( $XFOR ), setting the rating to Buy with a target price of 3.5 → 5.

0 · Reply

bowlerhatsftw Nov. 9 at 3:57 PM

$XFOR XFOR

0 · Reply

DARKP00L Nov. 7 at 7:48 PM

$XFOR the market is buzzing about this stock. Expect possible price changes!

0 · Reply

Market Cap	279.36M
Revenue (ttm)	2.56M
Net Income (ttm)	-37.45M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,462.89%
Debt to Equity Ratio	1.23

Volume	655,750
Avg Vol	964,448
Day's Range	N/A - N/A
Shares Out	87.44M
Stochastic %K	24%
Beta	0.42
Analysts	Strong Sell
Price Target	$7.38